42067-83-4

Upstream product

• 579-74-8 2-Methoxyacetophenone 
• 555-16-8 4-nitrobenzaldehdye 
• 135-02-4 ortho-anisaldehyde 
• 100-19-6 (4-nitrophenyl)ethanone 

Downstream Products

• 141885-66-7 (2-Methoxy-phenyl)-[4-(4-nitro-phenyl)-2,5-diphenyl-2H-pyrazol-3-yl]-methanone 
• 141885-71-4 (2-Methoxy-phenyl)-[4-(4-nitro-phenyl)-2,5-diphenyl-3,4-dihydro-2H-pyrazol-3-yl]-methanone 

Relevant academic research and scientific papers

Novel pyrazoline derivatives and the use thereof

The present invention relates to a novel pyrazoline derivative compound, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating cancer, containing the pyrazoline derivative compound or the pharmaceutically

Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor

A series of pyrazoline derivatives (5) were synthesized in 92-96% yields from chalcones (3) and hydrazides (4). Subsequently, topo-I and IIα-mediated relaxation and antiproliferative activity assays were evaluated for 5. Among the tested compounds, 5h had

ALLOSTERIC INHIBITORS OF ATYPICAL PROTEIN KINASES C

The invention provides specific small molecule compounds that allosterically regulate the activity of atypical protein kinase C, their use as a medicament, and their use in the treatment and prevention of allergic, inflammatory and autoimmune disorders, cancer, hyperproliferation, sepsis, viral and protozoan infections, dementing diseases, metabolic, sclerotic and osteoporotic disorders.

Discovery and optimization of 1,3,5-trisubstituted pyrazolines as potent and highly selective allosteric inhibitors of protein kinase C-χ

There is increasing evidence that the atypical protein kinase C, PKCχ, might be a therapeutic target in pulmonary and hepatic inflammatory diseases. However, targeting the highly conserved ATP-binding pocket in the catalytic domain held little promise to

NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER

Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

Solvent free synthesis of 1,3-diaryl-2-propenones catalyzed by commercial acid-clays under ultrasound irradiation

This paper presents a novel solvent free method of synthesis of trans-chalcones. The method was based on ultrasound irradiation of the reagents (aryl methyl ketones and aryl aldehydes) in presence of commercial acid-montmorillonites as catalysts. The trans-chalcones were synthesized in high yields (85-95%) and excellent selectivity in a short reaction time.